Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18244960 | 0.82 | TRPA1 (0.35) | — | |
| SCHEMBL287060 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL7284036 | 0.74 | CYP1A2 (0.50) | CYP1A2CYP2D6 | |
| SCHEMBL28647463 | 0.74 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL7484113 | 0.74 | — | — | |
| SCHEMBL1443231 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL4275672 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL8103830 | 0.72 | CYP1A2 (0.30) | CYP1A2CYP2D6 | |
| SCHEMBL134494 | 0.71 | — | — | |
| SCHEMBL2568072 | 0.70 | CYP1A2 (0.38) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888082-B1 | MOTILIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7582611-B2 | Treating disorders of gastric motility; decreasing side effects of erythromycin A | PFIZER INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1888082-A4 | MOTILIDE COMPOUNDS | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1888082-A1 | MOTILIDE COMPOUNDS | Pfizer, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| CN-1303994-C | Taxol vesicle injection and its prepn | ZHEJIANG HAIZHENG PHARMACEUTIC (CN) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006127252-A1 | MOTILIDE COMPOUNDS | PFIZER, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270616-A1 | Motilide compounds | PFIZER INC. | 2006-11-30 | — | — | US | disclosed |
| CN-1526387-A | Taxol vesicle injection and its prepn | 浙江海正药业股份有限公司 | 2004-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270616-A1 | Motilide compounds | MLNR, PROKR1, GIPR | CYP1A2 1502/4885CYP2D6 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.